Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Rare, aggressive subtype of pediatric acute lymphoblastic leukemia has surprisingly few mutations

Rare, aggressive subtype of pediatric acute lymphoblastic leukemia has surprisingly few mutations

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Finding may help advance experimental approach to improving public health

Finding may help advance experimental approach to improving public health

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Georgia State signs license agreement with Cisen to develop compounds for treating cancer

Georgia State signs license agreement with Cisen to develop compounds for treating cancer

Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

INRS researchers explore cellular and molecular mechanisms that affect AgNP particles

INRS researchers explore cellular and molecular mechanisms that affect AgNP particles

Lupus Research Institute announces this year's Novel Research Grants

Lupus Research Institute announces this year's Novel Research Grants

Facts about precision medicine

Facts about precision medicine

TKI introduction improves French CML patient survival

TKI introduction improves French CML patient survival

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.